临床试验公共管理平台 Clinical Trial Management Public Platform

1.Screening and Recruitment

1.1.Inclusion Criteria

Age	63 岁
patients with coronary heart disease	Yes
Sign the informed consent	Yes
Risk stratification for patients with low or middle risk	low rrisk

1.2.Exclusion Criteria

Patients in one of the following condition are excluded	none

Patients in one of the following condition are excluded

none

1.3.Basic Information of Subjects

Name	ZHZY
gender	女
people	汉
Height	156 cm
weight	57 kg
abdomen circumference	89 cm
left ventricular ejection fraction(LVEF)	61
stents implanted	No
anamnesis	others
Body Mass Index	23.73 kg/m2
smoking history	Yes
blood cholesterol level in hospital	5.51 mmol/l
drink history	Yes
Bad mood performance	none
exercise habit	No
The drug	antiplatelet drug / others

2.baseline index

2.1.Clinical Index

heart rate in anaerobic domain	99 次/分
heart rate in the peak oxygen uptake	111 次/分
blood pressure in Anaerobic domain	157/85 mm/Hg
blood pressure in the peak oxygen uptake	166/88 mm/Hg
the oxygen uptake in the rest	0.241 ml/kg/min
the oxygen uptake in anaerobic threshold	0.595 ml/kg/min
Peak oxygen uptake	0.809 ml/kg/min
target heart rate	97 次/分
Treadmill load	26 w
blood pressure in the rest	79 次/分
blood pressure in the rest	125/77 mm/Hg

2.3.Biomarkers in plasma

Phosphodiesterase 9A	ng/ml
Inflammatory factors	ng/ml
Immune-modulatory marker	ng/ml
left ventricular dysfunction marker	ng/ml
myeloperoxidase	ng/ml
adiponectin	ng/ml
extracellular-matrix remodeling markers	ng/ml

3.At the end of the treatment

3.1.Clinical Index after treatment

heart rate in anaerobic domain	112 次/分
heart rate in the peak oxygen uptake	114 次/分
blood pressure in the rest	148/79 mm/Hg
blood lipid level in Peak oxygen uptake period	154/82 mm/Hg
the oxygen uptake in the rest	0.232 ml/kg/min
the oxygen uptake in anaerobic threshold	0.820 ml/kg/min
Peak oxygen uptake	0.867 ml/kg/min
target heart rate	100 次/分
Treadmill load	45 w
heart rate in the rest	74 次/分
blood pressure in the rest	104/66 mm/Hg

3.2.Biomarkers in plasma after treatment

Phosphodiesterase 9A	ng/ml
Inflammatory factors	ng/ml
Immune-modulatory marker	ng/ml
left ventricular dysfunction marker	ng/ml
myeloperoxidase	ng/ml
adiponectin	ng/ml
extracellular-matrix remodeling markers	ng/ml

4.Follow-up after 3 months

Patients with follow-up of 3 months is discomfort or not	No
stick to exercise or not in the follow-up after 3 months	Yes

Patients with follow-up of 3 months is discomfort or not

stick to exercise or not in the follow-up after 3 months

Yes